Dr. Shengrong Guo received his Ph.D. in polymer physics & chemistry from Zhejiang University in 1995. He joined Fudan University as a Lecturer of Pharmaceutics in 1996 and was promoted to Associate Professor in 1999. He then moved to Shanghai Jiaotong University in 2000 and was promoted to Professor, Principal Investigator, and Director of the Group of Biomedical Polymer and Drug Controlled Release in 2003. In addition to his research endeavors, he has demonstrated a deep commitment to mentoring and guiding students. He has supervised the successful completion of numerous Master's dissertations and Ph.D. theses as both the main and co-advisor. He actively advises students in multiple roles, continuing his dedication to fostering the next generation of researchers. He has received recognition throughout his career for his contributions, including prestigious awards such as the Outstanding Life Science Award (2007, Mingzhi Ruye Life Science Awards, Administration Committee), the Pharmaceutical Science Award (2008, Pharmaceutical Association of Shanghai), the Pharmaceutical Science Award (2011, Chinese Pharmaceutical Association), etc. His group focuses on novel drug delivery systems for cancer treatment, including nanomedicines and medical device/drug combinations.
Dr. Shengrong Guo received his Ph.D. in polymer physics & chemistry from Zhejiang University in 1995. He joined Fudan University as a Lecturer of Pharmaceutics in 1996 and was promoted to Associate Professor in 1999. He then moved to Shanghai Jiaotong University in 2000 and was promoted to Professor, Principal Investigator, and Director of the Group of Biomedical Polymer and Drug Controlled Release in 2003. In addition to his research endeavors, he has demonstrated a deep commitment to mentoring and guiding students. He has supervised the successful completion of numerous Master's dissertations and Ph.D. theses as both the main and co-advisor. He actively advises students in multiple roles, continuing his dedication to fostering the next generation of researchers. He has received recognition throughout his career for his contributions, including prestigious awards such as the Outstanding Life Science Award (2007, Mingzhi Ruye Life Science Awards, Administration Committee), the Pharmaceutical Science Award (2008, Pharmaceutical Association of Shanghai), the Pharmaceutical Science Award (2011, Chinese Pharmaceutical Association), etc. His group focuses on novel drug delivery systems for cancer treatment, including nanomedicines and medical device/drug combinations.